Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.
While early adopters of Illumina's $1,000 genome machine the HiSeq X Ten have been testing the system for months, researchers from less wealthy organizations have had no access to the technology. In a limited way that changed this week, when the Garvan Institute of Medical Research, DNAnexus and AllSeq teamed up to share data from a HiSeq X Ten.
The National Institutes of Health (NIH) has awarded $14.5 million in eight grants to researchers working to develop high quality and low cost DNA sequencing. The grants are each for two to four years and are awarded through the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute, a part of NIH.
After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.
Enzymatics is expanding its offerings in the DNA sequencing market with the buyout of startup ArcherDx, which provides kits and software for evaluating cancer treatment. Add up the cash, Enzymatics equity and potential milestone fees in the deal, and the buyout could be worth up to $50 million.
Roche has unveiled a software update for improving DNA sequencing studies, for which advances in information technology have become crucial to improving accuracy and speed of 'omics data analysis.
For most people in the Western world, the mention of tuberculosis is likely to conjure up images of the Victorians. In richer countries, tuberculosis is, for the most part, a thing of the past.
University of Wisconsin researchers have undertaken a genomic study involving patients with cystic fibrosis, aiming to uncover data that explain variation in symptoms among those afflicted with the genetic lung disease. And researchers believe that bioinformatics and other new resources give them an "edge" in the fight to improve treatments, according to the university's release.
Roche has developed web-based software that enables the company's customers to quickly design sequence libraries and improve the process of target enrichment custom design for next-generation sequencing.